• SNS-032 and SARS-CoV-2 Host-Factor Evidence

  2026-10-12

  Kerr et al. identified vesicle-mediated transport, including Rab11a-linked cargo delivery, as a SARS-CoV-2 release-associated pathway and reported inhibition with CDKI-73. These findings should not be treated as evidence that SNS-032 was tested or that its cancer-model pharmacology translates into antiviral activity.

• What 5′ UTR Comparisons Really Show

  2026-10-11

  A 2026 comparison reports that bovine β-globin 5′ UTR supported stronger translation of several reporter and antigenic proteins than the other tested UTRs. The finding is relevant to mRNA construct design in a narrow experimental context, but it does not establish that EZ Cap™ Mouse IL-12 mRNA (m1Ψ) has superior expression, cytokine activity, delivery, or therapeutic performance.

• Recombinant Human Oncostatin M in HCC Adaptation

  2026-10-10

  Recombinant Human Oncostatin M offers a defined cytokine input for studying how extracellular signaling may intersect with ALKBH5-driven adaptation in hepatocellular carcinoma. This evidence-focused article separates established product biology from emerging hypotheses based on a 2026 sorafenib-resistance study.

• SDF-1beta (CXCL12) in Brucella Host-Cell Biology

  2026-10-09

  SDF-1beta (CXCL12), human recombinant, offers a defined way to examine chemokine context around host-cell phenotypes. This article interprets the 2026 Brucella CRISPR screen through a CXCL12-centered lens while separating demonstrated mechanisms from testable hypotheses.

• AY 9944 Dihydrochloride: Evidence and Limits

  2026-10-09

  AY 9944 dihydrochloride is a research compound used to study DHCR7, cholesterol biosynthesis, and 7-dehydrocholesterol biology. This overview compares supplier-described pharmacology with a 2026 grass carp gene-disruption study linking dhcr7 deficiency to improved resistance against grass carp reovirus, while separating genetic evidence from unproven claims about chemical inhibition, mammalian immunity, or therapeutic use.

• Dimethyloxalylglycine (DMOG) Overview

  2026-10-08

  Dimethyloxalylglycine (DMOG; SKU A4506) is described by APExBIO as a cell-permeable competitive PHD inhibitor for conceptual studies of HIF stabilization and hypoxia-related signaling. No matched paper evidence is available for this product entry.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-08

  This source-grounded overview examines Pomalidomide, also known as CC-4047, in the context of multiple myeloma and broader hematological malignancy research. It distinguishes findings from the primary multiple myeloma cell-line literature from claims reported in a supplier description, emphasizing model selection, tumor microenvironment modulation, evidence strength, and applicability limits.

• Lactate, HMGB1, and Exosomal Signaling in Sepsis

  2026-10-07

  Yang et al. identify a mechanistic link between elevated lactate and HMGB1 release during polymicrobial sepsis. The study connects lactate uptake and GPR81-associated signaling with HMGB1 lactylation, acetylation, exosomal export, and increased endothelial permeability, while also defining important boundaries for interpretation.

• IL-7, Human Recombinant: An ER Biology Lens

  2026-10-07

  IL-7, human recombinant provides a useful immunology context for interpreting ER proteostasis research. This article examines how SARS-CoV-2 PLpro reshapes ER-associated degradation and explains where IL-7 can inform, but not replace, mechanistic evidence.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-06

  Pomalidomide, also known as CC-4047, is an immunomodulatory compound studied in multiple myeloma and other hematological malignancy research. This overview separates established mechanism, cell-line genomics, supplier-reported findings, conceptual applications, and evidence limitations, with particular attention to tumor microenvironment modulation, drug resistance, and erythroid progenitor cell differentiation.

• CREATE: RNA-Based Gene Editing Without DSBs

  2026-10-06

  The CREATE platform combines CRISPR/Cas9 targeting with LINE-1-mediated reverse transcription to insert an RNA-encoded payload without relying on a CRISPR-induced double-strand break or DNA donor template. In the reference study, CREATE enabled insertion of a 1.1 kb promoter–GFP cassette in human cell lines and primary T cells, while reported off-target assessment found no observed unintended events within the study scope.

• Triptolide (PG490): From Transcription to Translation

  2026-10-05

  Triptolide, also known as PG490, offers translational researchers a mechanistic lens on transcriptional stress, immune regulation, tumor invasion, and inflammatory tissue injury. This perspective connects established product intelligence with a 2025 acute pancreatitis study while defining evidence boundaries.

• Pomalidomide (CC-4047): Evidence and Research Context

  2026-10-05

  A source-grounded overview of Pomalidomide and CC-4047 research, distinguishing supplier-reported pharmacology from peer-reviewed evidence on multiple myeloma cell-line genetics, drug response, model selection, and translational limitations.

• Sulfo-NHS-SS-Biotin for Surface Proteostasis

  2026-10-04

  Sulfo-NHS-SS-Biotin is more than a cleavable surface-labeling reagent: it can help frame how receptor abundance, trafficking, and function are interpreted. This article connects its chemistry with the IRE1/XBP1s proteostasis findings reported for trafficking-deficient GABA A receptors.

• EZ Cap™ Mouse IL-12 mRNA Overview

  2026-10-03

  A concise, source-limited overview of APExBIO’s EZ Cap™ Mouse IL-12 mRNA (m1Ψ), covering documented identity, conceptual research scope, and evidence limitations without matched paper evidence.

8533 records 1/569 page Next 12345 下5页 Last page